Background/Aim: Diabetes predisposes the affected individual to long term macro- and microvascular complications. Renal complications represent a major turning point in the life of people with diabetes. Adropin is a peptide primarily secreted by the liver and brain. It is encoded by the Energy Homeostasis Associated gene (Enho). Adropin main function is to prevent insulin resistance, dyslipidemia, and impaired glucose tolerance. This study aimed to assess the serum adropin level in type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN) patients.
Subject and Methods: This case control study was conducted on 50 diabetic patients from
Inpatient and Outpatient clinics of Internal Medicine Department, Benha University Hospitals, Egypt in addition to 25 apparently healthy controls. Upon their informed consent, and after complete history taking and full clinical examination, blood samples were taken for biochemical analysis and serum adropin level measurement. Adropin was measured using ELISA technique. Fasting and two hours post prandial blood glucose, HbA1C, blood urea, serum creatinine and
Glomerular Filtration Rate (GFR) were done.
Results: This study demonstrated that adropin show significant reduction in the diabetic group when compared with the control group and also exhibit significant decline in the DN group when compared with the diabetic group. There was a significant negative correlation between adropin and T2DM duration as well as with HbA1C (r = -0.552 & -0.467 and P = 0.001 & 0.001 respectively). Also, there was a significant positive correlation between adropin and estimated glomerular filtration rate (eGFR) (r = 0.358 and P = 0.002).
Conclusion: Adropin is significantly reduced in T2DM when compared with normal subjects and
the reduction of adropin is correlated with the deterioration in kidney functions manifested by the
reduction in eGFR. These findings suggested that the reduction of serum adropin may play a role in the pathogenesis of T2DM and DN. |
